TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean intraoperative Blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative Haemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: maximum plasma concentration of CP-675,206
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC, defined as the area under the concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: failure of NIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral Blood All-cell Donor Chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in treated area appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical Relapse Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of acute respiratory distress syndrome following cardiac surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to Normalization of Hypothalamic-Pituitary-Adrenal Axis (HPAA) Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AUCinf of Tenofovir Alafenamide (TAF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of Tenofovir Alafenamide (TAF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUClast of Tenofovir Alafenamide (TAF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Distribution of contraceptive method chosen
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Incidence of Malignancy
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Clinically Important Hepatic Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of Lipodystrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Probing Depth (PD) ≥5 mm with Bleeding on Probing (BoP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumour Control Probability (TCP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Normal Tissue Complication Probability (NTCP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric emptying kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: GI transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diagnostic performance of DAMS 3 test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titer Ratios of Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Negative appendicectomy rate
Endpoint domain: Adverse events/effects
Primary endpoint: post-op BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-op gastroœsophageal reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent of clinic patients with controlled blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Description and characteristics of culprit lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Vortioxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-24h) of Vortioxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t½ of Vortioxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All cause mortality at Day 28
Endpoint domain: Mortality/survival
Primary endpoint: Patient's satisfaction and confidence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rating of non-technical performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Day 28 Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With HCV NS3/4a Protease and NS5A Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Refractive results - spherical equivalent in diopters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diaphragm Thickening fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hormone levels in blood and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: TIMI 2/3 patency of the infarct-related artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Completion rates of non-routine tests
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of skin alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of GDC-9545
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Titers of Anti-HPV-16 and Anti-HPV-18 Neutralizing Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: S-100B levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with confirmed influenza infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Self-Assessed Pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Combined Unique Active MRI Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average Numeric Symptom Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average PLMWI (Periodic Leg Movement Index During Wakefulness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Domains
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Subjective Rating of Overall Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: slope of pupil diameter change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Domain-specific Risk-Taking
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Saliva hepcidin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent change from baseline UACR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Echocardiographic markers of cardiac strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of Potential Drug Interactions
Endpoint domain: Adverse events/effects
Primary endpoint: systole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: diastole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean ABP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pain following procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of consumption of SDG
Endpoint domain: Adverse events/effects
Primary endpoint: Kidney damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Delta Medio-lateral Postural Sway Range (Foam)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta of the Variability of Stride Time While Walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Social And Emotional Well-Being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vaccination adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intervention Costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to Pass Guidewire After Attaining Starting Point
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recurrence/exacerbation of symptomatic venous thromboembolism (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of patients totally eradicated for S. aureus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Diabetes Unawareness Prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carrier Rate for Staphylococcus Aureus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: MSSA Clearance Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: MRSA Clearance Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinical characteristics of patients with movement disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intra-procedural Heparin Requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent change in left ventricular volume index (LVVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postural control (sway velocity center of pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ketosis (Beta-hydroxybutyrate Levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time-weighted Sum of Pain Relief (PAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of SPN-812 assessed by SKAMP-CS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of subjects surviving with good neurologic outcome
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Concentration (Cmax) of Plasma Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Profile (AUClast) of Plasma Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Amount Eliminated Via Urine Over an 8-Hour Period (Ae0-8) of Losartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrinsic myocardial contractile force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Histological response of soft tissue sarcoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite neurocognition scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Psoriasis area severity index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of clinically significant PONV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to remove CO2 (≥50 mL/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cognitive functioning - Sustained attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Normal Vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fasting Serum Triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of patient satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Death Within 8 Weeks of Infusion
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Immediate and Short Term Toxicity of Infusion Over 8 Weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Peak Transgene Copy Number Per 1000ng PBMC DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain and Functional Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Edema From Baseline to Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in leisure-time and transport-related physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temperature at the end of the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart failure medications compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of subjects who experience serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects who experience deaths
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects who experience adverse events (AEs) leading to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Odds ratio of immunization effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modifications in hemostasis parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of ECT treatments for 50% reduction in MADRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: antitumour activity of CP-4055
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bleeding index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free T3 (FT3) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Wave intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count and Percentage of Participants Experiencing Any Grade 2 or Higher Clinical Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative radiological step-off reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tamoxifen AUCinf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endoxifen AUCinf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IBS-SSS (Severity Symptom Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chin advancement measure assessing the stability of the result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: D. Farinae Specific IgG4 Change From Baseline to End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Costs for the clinics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Social anxiety symptoms measured by SIAS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Social anxiety symptoms measured by SPIN
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Social anxiety symptoms measured by BSPS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of warfarin adjustments required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in therapeutic, sub-, and supra-therapeutic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombotic/bleeding episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Executive Cognitive Function Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Insight Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Remission Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: relapse rate of MNE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NOSE total scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Specific conductance (SGaw)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced expiratory volume in 1 sec (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Occurrence of clinically relevant adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Peripheral Arterial Tone Apnea-hypopnea Index (PAHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of clinical pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Occurrence of miscarriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Periprosthetic bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hospitalized infections
Endpoint domain: Adverse events/effects
Primary endpoint: Hospitalized pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Opportunistic infections
Endpoint domain: Adverse events/effects
Primary endpoint: Glycosylated Haemoglobin (HbA1c) Value < 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Evolution of Fasting Plasma Glucose (FPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in functional muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline in Central Subfield Thickness (CSFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Death, Stroke, and Myocardial Infarction
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free survival (PFS) failure rate
Endpoint domain: Mortality/survival
Primary endpoint: venous oxygen saturation accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: rCBF changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Change From Baseline in Dynamic Allodynia Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Change From Baseline in Mechanical Pain Sensitivity (Von Frey)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Change From Baseline in Cold Pain Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: RBC and WBC cellular properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adhesive properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Therapeutical Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of repeat pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Subject global assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in baseline disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Achievement ratio of 50% dose reduction of (non-)BZD hypnotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of Buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of Buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Δ percentage (%) of anti-pneumococcal vaccination at 6-month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heel Tenderness Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Foot and Ankle Outcome Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: American Orthopaedic Foot and Ankle Society Ankle-Hindfoot Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dyspnea change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AUC From Time Zero to Last Quantifiable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma treatment satisfaction and control grading
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Successful Capture of Peripheral Capillary Oxygen Saturation (SpO2) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Communication performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Predictive and diagnostic accuracy of H2FPEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication Regimen Completion Rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of HIV-1 Infected Participants
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline sore throat at 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline postoperative cough at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline postoperative snoring at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes